ProCE Banner Activity


Overcoming Barriers to Timely Diagnosis and Classification of Interstitial Lung Disease: Considerations for Radiologists


Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 26, 2023

Expiration: October 25, 2024



David Lynch

David Lynch, MB, BCh

Professor of Radiology
Medical Director
Quantitative Imaging Laboratory
National Jewish Health
Denver, Colorado

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This educational initiative is intended for community- and academic-based radiologists and other healthcare providers who care for patients with or at risk for Interstitial Lung Disease (ILD). 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of radiologists in timely in accurate diagnosis of ILD including identification, referral, and follow-up of ILA, as well as radiologic patterns consistent with fibrosis ILDs and importance of MDD in the diagnosis and classification of ILD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify clinical and imaging patterns used in the diagnosis and classification of interstitial lung disease (ILD)

  • Integrate current guideline-based HRCT patterns necessary for the diagnosis of idiopathic pulmonary fibrosis (IPF)

  • Discuss how multidisciplinary discussion (MDD) improves accuracy and confidence in making the diagnosis and classification of ILD

  • Construct a follow-up and referral plan for identified interstitial lung abnormalities (ILA) in the context of patient-specific characteristics


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

David A. Lynch, MB, BCh: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Calyx, Daiichi Sankyo.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 26, 2023, through October 25, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of  1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.